United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $538.00, for a total transaction of $5,111,000.00. Following the sale, the chief executive officer owned 130 shares of the company’s stock, valued at approximately $69,940. This represents a 98.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $530.35 on Thursday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $548.12. The company has a market capitalization of $23.25 billion, a price-to-earnings ratio of 19.01, a PEG ratio of 1.94 and a beta of 0.84. The company has a 50-day simple moving average of $488.85 and a 200 day simple moving average of $465.99.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business’s revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the firm earned $6.19 EPS. Sell-side analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on UTHR. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. UBS Group lifted their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. TD Cowen boosted their target price on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Finally, Wells Fargo & Company raised their price target on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 26th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $548.09.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AXQ Capital LP increased its holdings in United Therapeutics by 495.4% in the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after buying an additional 3,235 shares during the period. AE Wealth Management LLC lifted its holdings in shares of United Therapeutics by 396.3% during the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after acquiring an additional 3,424 shares during the period. Great Lakes Advisors LLC lifted its holdings in shares of United Therapeutics by 194.7% during the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after acquiring an additional 2,975 shares during the period. Optimize Financial Inc acquired a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $444,000. Finally, Simplify Asset Management Inc. acquired a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $8,351,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.